SCHEMBL5206502

SCHEMBL5206502

NC(=O)CNC(=O)c1cc(=O)c2ccccc2o1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.72
HTT P42858 2/20 0.59
KDM4E B2RXH2 1/20 0.59
USP2 O75604 1/20 0.59
CSNK2A2 P19784 1/20 0.59
PTGS1 P23219 1/20 0.59
CSNK2B P67870 1/20 0.59
CSNK2A1 P68400 1/20 0.59
CSNK2A3 Q8NEV1 1/20 0.59
MAOA P21397 2/20 0.58
MAOB P27338 2/20 0.58
RECQL P46063 1/20 0.57
MEN1 O00255 3/20 0.56
KMT2A Q03164 3/20 0.56
NPC1 O15118 3/20 0.56
RAB9A P51151 3/20 0.56
POLB P06746 3/20 0.56
MAPT P10636 2/20 0.56
ALDH1A1 P00352 2/20 0.56
SMN1; SMN2 Q16637 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27582528 0.89 LMNA (0.77) LMNAHTTKDM4EUSP2CSNK2A2
SCHEMBL19744072 0.84 LMNA (1.00) LMNAHTTKDM4EUSP2CSNK2A2
SCHEMBL19743978 0.82 LMNA (0.71) LMNAHTTKDM4EUSP2CSNK2A2
SCHEMBL8292253 0.81 TP53 (0.68) USP2MEN1KMT2ANPC1RAB9A
SCHEMBL21174969 0.80 LMNA (0.80) LMNAHTTKDM4EUSP2CSNK2A2
SCHEMBL5274120 0.80 LMNA (0.67) LMNAHTTKDM4EUSP2CSNK2A2
SCHEMBL19745162 0.79 LMNA (0.74) LMNAHTTKMT2APOLBALDH1A1
SCHEMBL8645195 0.79 LMNA (0.67) LMNAHTTKDM4EUSP2CSNK2A2
SCHEMBL21174951 0.79 LMNA (0.66) LMNAHTTKDM4EUSP2CSNK2A2
Chromocarb SCHEMBL11033175 0.79 KDM4E (0.69) LMNAHTTKDM4EUSP2CSNK2A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1363925-B8 MACROLIDE ANTIBIOTICS GLAXO GROUP LTD (GB) 2007-04-25 EP disclosed
EP-1363925-B1 MACROLIDE ANTIBIOTICS GLAXO GROUP LTD (GB) 2006-11-15 EP disclosed
US-20060211636-A1 Macrolide Antibiotics ALIHODZIC SULEJMAN 2006-09-21 US disclosed
US-20050215495-A1 Macrolide antibiotics ALIHODZIC SULEJMAN 2005-09-29 US disclosed
US-20040077557-A1 Macrolide antibiotics GLAXO GROUP LIMITED (GB) 2004-04-22 US disclosed
EP-1363925-A1 MACROLIDE ANTIBIOTICS GLAXO GROUP LIMITED (GB) 2003-11-26 EP disclosed
WO-2002050091-A1 MACROLIDE ANTIBIOTICS GLAXO GROUP LIMITED (GB) 2002-06-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050215495-A1 Macrolide antibiotics IL1R1, MRPL12, RPS21 LMNA 1672/4885HTT 3482/4885KDM4E 1204/4885
US-20060211636-A1 Macrolide Antibiotics IL1R1, MRPL12, RPS21 LMNA 1672/4885HTT 3482/4885KDM4E 1204/4885
US-20040077557-A1 Macrolide antibiotics MALT1, MRPL21, IL1R1 LMNA 1504/4885HTT 3592/4885KDM4E 1358/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.